FGF21
Biological
Teva Pharmaceuticals USA, Inc.
Total Payments
$57,403
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $57,403 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $57,403 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TV47948-SAD-10122 | Teva Pharmaceuticals USA, Inc. | $57,403 | 0 |
Top Doctors Receiving Payments for FGF21
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Lenexa, KS | $57,403 | 1 |
Ad
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $57,403
Product Information
- Type Biological
- Total Payments $57,403
- Total Doctors 0
- Transactions 1
About FGF21
FGF21 is a biological associated with $57,403 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $57,403 was paid across 1 transactions to 0 doctors.
The most common payment nature for FGF21 is "Unspecified" ($57,403, 100.0% of total).
FGF21 is associated with 1 research study, including "TV47948-SAD-10122" ($57,403).